Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hutchmed Share News (HCM)
HCM Share
Price
HCM Share
News
HCM Share
Chat
HCM Share
Trades
HCM
Live RNS
HCM Share
Charts
HCM Level 2
Console
HCM Live
Share Price
HCM Broker
Ratings
HCM Directors
Deals
HCM Financial
Diary
HCM
Fundamentals
HCM Short
Positions
HCM
Media
HCM Company
Research
HCM Company
Timeline
Share Price Information for Hutchmed (HCM)
Last checked at -
Last checked at 
Intraday Hutchmed Share Chart
Hutchmed News
TRADING UPDATES: Tungsten secures loan; Ashtead trading in line
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
EARNINGS AND TRADING: AltynGold reports annual revenue surge
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...
Hutchmed begins phase-three trials of lymphoma therapy in China
(Alliance News) - Hutchmed China Ltd on Monday said it had begun phase-three clinical trials of its lymphoma treatment in China.
LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich
(Alliance News) - GSK makes regulatory progress in Japan for a cancer therapy, Anglo American moves to delist from the Swiss exchange as part of its r...
Hutchmed shares slide as recalls cancer treatment Tazverik
(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen ...
Hutchmed China 2025 profit surges on divestment but revenue falls
(Alliance News) - Hutchmed China Ltd on Thursday reported lower revenue for 2025, but reported sharply higher profit following a major divestment gain...
Hutchmed China shares rise as tumour treatment trial begins
(Alliance News) - Hutchmed China Ltd on Wednesday said it had launched a Phase I/IIa clinical trial of its cancer treatment HMPL-A580.
Follow the stocks
